Emerging roles and potential clinical applications of long non-coding RNAs in hepatocellular carcinoma - 31/08/22

Abstract |
Hepatocellular carcinoma is one of the most common highly malignant tumors in humans, as well as the leading cause of cancer-related death worldwide. Growing evidence has indicated that lncRNAs are implicated in different molecular mechanisms, including interactions with DNA, RNA, or protein, so that to regulate the gene expression at epigenetic, transcriptional, or posttranscriptional level. Moreover, the mechanism of action of lncRNA is closely related to its subcellular localization. An increasing number of studies have certified that lncRNA plays a significant biological function in the occurrence and development of hepatocellular carcinoma, such as involving in cell proliferation, metastasis, apoptosis, ferroptosis, autophagy, and reprogramming of energy metabolism. As a result, lncRNA has great potential as a novel biomarker for diagnosis or therapeutics of hepatocellular carcinoma. In this review, we highlight the correlation between subcellular localization of lncRNA and its mechanism of action, discuss the biological roles of lncRNA and the latest research advances in hepatocellular carcinoma, and emphasize the potential of lncRNA as a therapeutic target for advanced patients of hepatocellular carcinoma.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | LncRNA plays crucial roles in hepatocellular carcinoma (HCC). |
• | The function of lncRNA is determined by its subcellular localization |
• | LncRNA mediate HCC cell proliferation, death and metastasis. |
• | LncRNA may serve as promising therapeutic target for patients with advanced HCC. |
Abbreviations : HCC, lncRNA, PRC2, Pol II, CDK, EMT, TNF, Dox, LDHA, PKM2, HK2, FA, ATGL, DAG, FFA, HDGF, GLS1, SRPK2, TRAF6, NF‐κB, HDAC1, p300, SMRT, PI3K, STAT3, TKT
Keywords : Long noncoding RNA, Hepatocellular carcinoma, Energy metabolism, Cell proliferation, Apoptosis, Metastasis
Plan
Vol 153
Article 113327- septembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
